Expert Interview
A Second Opinion: Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Ticker(s): GPCR, NVO, LLYInstitution: Mayo Clinic
- Professor of Medicine & Consultant, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine at the Mayo Clinic.
- Manages 40 patients monthly with obesity.
- His lab studies the effects of obesity and how body fat (adipose tissue) and body fat distribution influence health; research involves measuring free fatty acid release in order to relate these factors to organ and tissue function with a goal of understanding the regulation of body fat and body fat distribution, in hopes of developing novel approaches to improve the health of humans affected by obesity or excess fat.
Roughly how many patients with obesity do you manage?
Added By: ben_adminOn a scale from 1-10 (10 being extremely excited) how would you rate your level of excitement for GSBR-1290?
Added By: ben_adminWill patients prefer an oral weight loss medication that is less efficacious than an injectable medication?
Added By: ben_adminHow do you interpret the high rates of vomiting/nausea seen in Structures phase 2a study?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
